Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q3

7446.TEDINET S100RLXQ
Period2022-10-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥26.9bn2022-10-01 → 2023-06-30Cons.Net sales
Revenue¥37.3bn2021-10-01 → 2022-09-30Cons.Net sales (5-year summary)
Revenue¥27.9bn2021-10-01 → 2022-06-30Cons.Net sales
Operating income¥659m2022-10-01 → 2023-06-30Cons.Operating income
Operating income¥763m2021-10-01 → 2022-06-30Cons.Operating income
Ordinary income¥708m2022-10-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥1.0bn2021-10-01 → 2022-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥814m2021-10-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥707m2022-10-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥786m2021-10-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥499m2022-10-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥658m2021-10-01 → 2022-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥539m2021-10-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥507m2022-10-01 → 2023-06-30Cons.Profit loss
Net income¥559m2021-10-01 → 2022-06-30Cons.Profit loss
Total assets¥17.8bnat 2023-06-30Cons.Assets
Total assets¥17.5bnat 2022-09-30Cons.Assets
Total assets¥15.0bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥10.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥10.8bnat 2022-09-30Cons.Liabilities
Net assets / equity¥7.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥6.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.6bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.4bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥1.4bnat 2022-09-30Cons.Cash and deposits
EPS (basic)¥553.842022-10-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.632023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥728.762021-10-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥596.992021-10-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥185.032022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio40.3%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio37.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio43.2%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2022-10-01 → 2023-06-30¥313m
Otherother segmentsrevenue external2022-10-01 → 2023-06-30¥313m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2022-10-01 → 2023-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2022-10-01 → 2023-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2022-10-01 → 2023-06-30¥13.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2022-10-01 → 2023-06-30¥13.5bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2022-10-01 → 2023-06-30¥10.6bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2022-10-01 → 2023-06-30¥10.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-10-01 → 2023-06-30¥26.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-10-01 → 2023-06-30¥26.9bn
Otherother segmentsrevenue2021-10-01 → 2022-06-30¥318m
Otherother segmentsrevenue external2021-10-01 → 2022-06-30¥318m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2022-06-30¥11.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2022-06-30¥11.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2022-06-30¥27.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2022-06-30¥27.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 382
ItemContextValueUnit
Noncurrent assetsPrior1YearInstant4810012000JPY
Noncurrent assetsCurrentQuarterInstant5235598000JPY
AssetsPrior1YearInstant17519610000JPY
AssetsCurrentQuarterInstant17755661000JPY
Notes and accounts payable tradePrior1YearInstant8766234000JPY
Notes and accounts payable tradeCurrentQuarterInstant8614643000JPY
Electronically recorded obligations operating clPrior1YearInstant339170000JPY
Electronically recorded obligations operating clCurrentQuarterInstant354762000JPY
Short term loans payablePrior1YearInstant170800000JPY
Short term loans payableCurrentQuarterInstant277000000JPY
Current portion of long term loans payablePrior1YearInstant14280000JPY
Current portion of long term loans payableCurrentQuarterInstant14280000JPY
Lease obligations clPrior1YearInstant155723000JPY
Lease obligations clCurrentQuarterInstant118225000JPY
Accounts payable otherPrior1YearInstant195928000JPY
Accounts payable otherCurrentQuarterInstant88530000JPY
Income taxes payablePrior1YearInstant199147000JPY
Income taxes payableCurrentQuarterInstant38643000JPY
Provision for bonusesPrior1YearInstant58100000JPY
Provision for bonusesCurrentQuarterInstant12300000JPY
Other clPrior1YearInstant185621000JPY
Other clCurrentQuarterInstant185965000JPY
Current liabilitiesPrior1YearInstant10085006000JPY
Current liabilitiesCurrentQuarterInstant9704351000JPY
Long term loans payablePrior1YearInstant41690000JPY
Long term loans payableCurrentQuarterInstant30980000JPY
Lease obligations nclPrior1YearInstant214998000JPY
Lease obligations nclCurrentQuarterInstant199761000JPY
Deferred tax liabilitiesPrior1YearInstant228928000JPY
Deferred tax liabilitiesCurrentQuarterInstant311072000JPY
Net defined benefit liabilityPrior1YearInstant91554000JPY
Net defined benefit liabilityCurrentQuarterInstant90846000JPY
Provision for directors retirement benefitsPrior1YearInstant131378000JPY
Provision for directors retirement benefitsCurrentQuarterInstant139112000JPY
Other nclPrior1YearInstant44605000JPY
Other nclCurrentQuarterInstant44560000JPY
Noncurrent liabilitiesPrior1YearInstant753155000JPY
Noncurrent liabilitiesCurrentQuarterInstant816333000JPY
LiabilitiesPrior1YearInstant10838162000JPY
LiabilitiesCurrentQuarterInstant10520684000JPY
Capital stockPrior1YearInstant820400000JPY
Capital stockCurrentQuarterInstant820400000JPY
Capital surplusPrior1YearInstant881100000JPY
Capital surplusCurrentQuarterInstant881100000JPY
Retained earningsPrior1YearInstant4494215000JPY
Retained earningsCurrentQuarterInstant4889621000JPY
Treasury stockPrior1YearInstant-168907000JPY
Treasury stockCurrentQuarterInstant-168907000JPY
Shareholders equityPrior1YearInstant6026808000JPY
Shareholders equityCurrentQuarterInstant6422214000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-09-30pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2023-06-30pass
statement vs summary · revenueconsolidated 2021-10-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-10-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-09-30pass
statement vs summary · total assetsconsolidated 2023-06-30pass